Clinical Trial Update: A Study to Compare Meloxicam IM Once Daily Versus Meloxicam Orally Once Daily in Patients With Rheumatoid Arthritis [Phase 3]

View source ↗

Summary

Phase 3 trial comparing intramuscular meloxicam once daily to oral meloxicam once daily in rheumatoid arthritis patients completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• MELOXICAM (MELOXICAM)
• Meloxicam IM (meloxicam)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Arthritis, Rheumatoid | Phase 3 | Status: COMPLETED